135 related articles for article (PubMed ID: 38619278)
1. Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.
Qin G; Dai J; Chien S; Martins TJ; Loera B; Nguyen QH; Oakes ML; Tercan B; Aguilar B; Hagen L; McCune J; Gelinas R; Monnat RJ; Shmulevich I; Becker PS
Clin Cancer Res; 2024 Jun; 30(12):2659-2671. PubMed ID: 38619278
[TBL] [Abstract][Full Text] [Related]
2. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
3. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
4. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
5. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
6. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
[TBL] [Abstract][Full Text] [Related]
7. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
Awada H; Durmaz A; Gurnari C; Kishtagari A; Meggendorfer M; Kerr CM; Kuzmanovic T; Durrani J; Shreve J; Nagata Y; Radivoyevitch T; Advani AS; Ravandi F; Carraway HE; Nazha A; Haferlach C; Saunthararajah Y; Scott J; Visconte V; Kantarjian H; Kadia T; Sekeres MA; Haferlach T; Maciejewski JP
Blood; 2021 Nov; 138(19):1885-1895. PubMed ID: 34075412
[TBL] [Abstract][Full Text] [Related]
8. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
9. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
10. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
12. A single-cell survey of cellular hierarchy in acute myeloid leukemia.
Wu J; Xiao Y; Sun J; Sun H; Chen H; Zhu Y; Fu H; Yu C; E W; Lai S; Ma L; Li J; Fei L; Jiang M; Wang J; Ye F; Wang R; Zhou Z; Zhang G; Zhang T; Ding Q; Wang Z; Hao S; Liu L; Zheng W; He J; Huang W; Wang Y; Xie J; Li T; Cheng T; Han X; Huang H; Guo G
J Hematol Oncol; 2020 Sep; 13(1):128. PubMed ID: 32977829
[TBL] [Abstract][Full Text] [Related]
13. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
Cortes JE
Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
[TBL] [Abstract][Full Text] [Related]
14. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
15. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
16. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
[TBL] [Abstract][Full Text] [Related]
17. Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
Honda A; Koya J; Yoshimi A; Miyauchi M; Taoka K; Kataoka K; Arai S; Kurokawa M
Exp Hematol; 2021 Sep; 101-102():42-48.e11. PubMed ID: 34333045
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Smith CC; Viny AD; Massi E; Kandoth C; Socci ND; Rapaport F; Najm M; Medina-Martinez JS; Papaemmanuil E; Tarver TC; Hsu HH; Le MH; West B; Bollag G; Taylor BS; Levine RL; Shah NP
Clin Cancer Res; 2021 Jul; 27(14):4003-4011. PubMed ID: 34103301
[TBL] [Abstract][Full Text] [Related]
19. HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia.
Zhou W; Xu S; Chen X; Wang C
Hematology; 2021 Dec; 26(1):170-178. PubMed ID: 33538241
[TBL] [Abstract][Full Text] [Related]
20. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]